vs
Side-by-side financial comparison of FinVolution Group (FINV) and Prestige Consumer Healthcare Inc. (PBH). Click either name above to swap in a different company.
FinVolution Group is the larger business by last-quarter revenue ($479.7M vs $283.4M, roughly 1.7× Prestige Consumer Healthcare Inc.). FinVolution Group runs the higher net margin — 21.2% vs 16.5%, a 4.7% gap on every dollar of revenue. Prestige Consumer Healthcare Inc. produced more free cash flow last quarter ($75.3M vs $70.6M).
Volution Group plc is a manufacturer of ventilation equipment for commercial and residential customers. Based in Crawley, West Sussex, the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.
FINV vs PBH — Head-to-Head
Income Statement — Q1 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $479.7M | $283.4M |
| Net Profit | $101.7M | $46.7M |
| Gross Margin | — | 55.5% |
| Operating Margin | 44.6% | 29.1% |
| Net Margin | 21.2% | 16.5% |
| Revenue YoY | — | -2.4% |
| Net Profit YoY | — | -23.5% |
| EPS (diluted) | — | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $283.4M | ||
| Q3 25 | — | $274.1M | ||
| Q2 25 | — | $249.5M | ||
| Q1 25 | $479.7M | $296.5M | ||
| Q4 24 | — | $290.3M | ||
| Q3 24 | — | $283.8M | ||
| Q2 24 | — | $267.1M | ||
| Q1 24 | — | $277.0M |
| Q4 25 | — | $46.7M | ||
| Q3 25 | — | $42.2M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | $101.7M | $50.1M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | — | $54.4M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | — | 29.1% | ||
| Q3 25 | — | 29.1% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | 44.6% | 29.8% | ||
| Q4 24 | — | 31.7% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 27.0% | ||
| Q1 24 | — | 29.7% |
| Q4 25 | — | 16.5% | ||
| Q3 25 | — | 15.4% | ||
| Q2 25 | — | 19.0% | ||
| Q1 25 | 21.2% | 16.9% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 19.2% | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | 17.9% |
| Q4 25 | — | $0.97 | ||
| Q3 25 | — | $0.86 | ||
| Q2 25 | — | $0.95 | ||
| Q1 25 | — | $1.00 | ||
| Q4 24 | — | $1.22 | ||
| Q3 24 | — | $1.09 | ||
| Q2 24 | — | $0.98 | ||
| Q1 24 | — | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $745.0M | $62.4M |
| Total DebtLower is stronger | — | $1.0B |
| Stockholders' EquityBook value | — | $1.8B |
| Total Assets | $3.4B | $3.5B |
| Debt / EquityLower = less leverage | — | 0.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $62.4M | ||
| Q3 25 | — | $119.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | $745.0M | $97.9M | ||
| Q4 24 | — | $50.9M | ||
| Q3 24 | — | $51.5M | ||
| Q2 24 | — | $34.3M | ||
| Q1 24 | — | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | — | $3.5B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | — | $3.4B | ||
| Q1 25 | $3.4B | $3.4B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.0M | $78.3M |
| Free Cash FlowOCF − Capex | $70.6M | $75.3M |
| FCF MarginFCF / Revenue | 14.7% | 26.6% |
| Capex IntensityCapex / Revenue | 0.3% | 1.1% |
| Cash ConversionOCF / Net Profit | 0.71× | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | $267.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $78.3M | ||
| Q3 25 | — | $57.5M | ||
| Q2 25 | — | $79.0M | ||
| Q1 25 | $72.0M | $61.8M | ||
| Q4 24 | — | $65.1M | ||
| Q3 24 | — | $69.8M | ||
| Q2 24 | — | $54.8M | ||
| Q1 24 | — | $66.9M |
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | $70.6M | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | 14.7% | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 0.71× | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FINV
Segment breakdown not available.
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
